CONCORDBIO - Swing Trade Analysis with AI Signals

Last Updated Time : 19 Sept 25, 2:15 pm

Swing Trade Rating: 3.0

📊 Technical & Momentum Overview

⚠️ Weak Momentum Signals

MACD (–22.6): Strong bearish divergence—momentum is fading.

RSI (47.6): Below neutral, indicating lack of strength.

Price Action: Trading below both 50 DMA (₹1,705) and 200 DMA (₹1,758), confirming a short-term downtrend.

Volume Dip: Current volume is ~10% below 1-week average—low participation.

📈 Fundamental Snapshot

✅ Positives

ROCE (28.4%) & ROE (21.4%): Strong capital efficiency.

EPS (₹34.2) vs P/E (48.9): Slightly stretched but supported by quality earnings.

Debt-to-Equity (0.00): Zero debt—adds margin of safety.

Book Value (₹173): Price-to-book ~9.6, typical for high-growth pharma.

🚨 Red Flags

PAT Qtr (₹42.6 Cr) vs Prev Qtr (₹142 Cr): Sharp earnings decline (–26.9%).

FII & DII Outflows: –0.25% and –0.31% respectively—sentiment softening.

PEG (1.82): Overvalued on growth-adjusted basis.

52W Index (24.6%): Weak relative performance—trading near lower end of yearly range.

🎯 Optimal Entry Price

Wait for Reversal Confirmation: Entry only above ₹1,705–₹1,720 with MACD flattening and RSI > 50

Aggressive Entry: ₹1,660–₹1,670 if volume spikes and RSI crosses 50

🚪 Exit Strategy (If Already Holding)

Target Exit: ₹1,750–₹1,780 (near 200 DMA and resistance zone)

Stop Loss: ₹1,610 (below recent support and VWAP)

Exit Trigger: RSI dips below 45 or MACD diverges further

Selva, CONCORDBIO is fundamentally strong but technically weak at the moment. If you're considering a tactical swing, it’s best to wait for confirmation signals. Want help scripting MACD reversal alerts or building a biotech basket with better PEG and volume trends?

Edit in a page